ইস্রায়েল - হিব্রু - Ministry of Health

abic marketing ltd, israel - fentanyl as citrate - טבליה - fentanyl as citrate 400 mcg - fentanyl

ইস্রায়েল - হিব্রু - Ministry of Health

abic marketing ltd, israel - fentanyl as citrate - טבליה - fentanyl as citrate 600 mcg - fentanyl

ইস্রায়েল - হিব্রু - Ministry of Health

abic marketing ltd, israel - fentanyl as citrate - טבליה - fentanyl as citrate 800 mcg - fentanyl

ইস্রায়েল - হিব্রু - Ministry of Health

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 15 mg - rivaroxaban

ইস্রায়েল - হিব্রু - Ministry of Health

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 20 mg - rivaroxaban

ইস্রায়েল - হিব্রু - Ministry of Health

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 2.5 mg - rivaroxaban

ইস্রায়েল - হিব্রু - Ministry of Health

glaxo smith kline (israel) ltd - ranitidine as hydrochloride - סירופ - ranitidine as hydrochloride 150 mg / 10 ml - ranitidine - ranitidine - h2 receptor antagonist. for treatment of duodenal ulcer and benign gastric ulcer, including that associated with nsaid agents. post-operative ulcer, oesophageal reflux disease and zollinger-ellison syndrome. prophylaxis of stress ulceration in seriously ill patients. before general anaesthesia in patients considered to be of risk acid aspiration (mendelson's syndrome).

ইস্রায়েল - হিব্রু - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

ইস্রায়েল - হিব্রু - Ministry of Health

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

ইস্রায়েল - হিব্রু - Ministry of Health

neopharm ltd - ranolazine 1000 mg - tablets extended release - ranolazine - ranexa is indicated for the treatment of chronic angina. ranexa is also indicated as add-on therapy for the symptomati treatment of patients with chronic angina who are inadequately controlled or intolerant to other first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ace inhibitors, and angiotensin receptor blockers.